However, our knowledge of GATA3 mutations in tumorigenesis, tumor progression, and acquisition of drug resistance is limited (Kouros-Mehr et al., 2006; Chou et al., 2010; Chou et al., 2013; Liu et al., 2016; Bi et al., 2020). The gene discussed is GATA3; the disease is neoplasm.